Ignite Creation Date:
2025-12-24 @ 11:51 AM
Ignite Modification Date:
2025-12-31 @ 6:24 AM
Study NCT ID:
NCT05782361
Status:
RECRUITING
Last Update Posted:
2025-08-20
First Post:
2023-01-13
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC
Sponsor:
Institute of Cancer Research, United Kingdom
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
CCR5558
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None